Repronex ANDA Approval On Close Identity To Pergonal Reasonable - Court

FDA's approval of an ANDA based on close chemical identities is reasonable, the Washington, D.C. court of appeals ruled Oct. 27 in vacating a lower court injunction against Ferring Pharmaceuticals' Repronex sought by Serono, manufacturer of the innovator menotropins product Pergonal.